The experiments with SMI 6877002 in EAE illustrate the therapeutic potential of CD40-TRAF6 targeting strategies (Figures 2B,C), with the ability to reduce monocyte recruitment and macrophage activation in the CNS and this approach could potentially be used as a cotreatment to ameliorate MS. The gene discussed is CD40; the disease is myeloid sarcoma.